MedPath

Effect of Calciterol and Cinacalcate on hyperparathyroidism

Phase 3
Conditions
Hyperparathyroidism.
Hyperparathyroidism and other disorders of parathyroid gland
Registration Number
IRCT20190702044076N1
Lead Sponsor
Shahre-kord University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
60
Inclusion Criteria

Consent to participate in the study
Having end-stage renal disease
Patients undergoing hemodialysis

Exclusion Criteria

Parathyroid hormone less than 300 pg / ml
Calcium higher than 10 mg / dl

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Phosphate. Timepoint: Before the intervention and 8 weeks after the intervention. Method of measurement: Serum levels of blood sample.;Parathyroid hormone. Timepoint: Before the intervention and 8 weeks after the intervention. Method of measurement: Serum levels of blood sample.;Calcium. Timepoint: Before the intervention and 8 weeks after the intervention. Method of measurement: Serum levels of blood sample.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath